Team:Calgary/Project/OurSensor/Reporter/BetaLactamase
From 2013.igem.org
Line 73: | Line 73: | ||
<h2>Results</h2> | <h2>Results</h2> | ||
- | <p>For characterization purposes, we tested the constructs with benzylpenicillin, a substrate that gives a colourimetric and a pH output. In the future, we will also characterize <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K782004"> | + | <p>For characterization purposes, we tested the constructs with benzylpenicillin, a substrate that gives a colourimetric and a pH output. In the future, we will also characterize <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K782004"><span class="Green"><b>TALE A</b></span></a>-linker-β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"> |
- | <span class="Green"><b> | + | |
- | TALE A | + | |
- | </b></span> | + | |
- | </a>-linker-β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"> | + | |
<span class="Green"><b> | <span class="Green"><b> | ||
BBa_K1189031 | BBa_K1189031 | ||
Line 83: | Line 79: | ||
</a >) in the presence of a nitrocefin which is the substrate we plan to use in our Biosensor.</p> | </a >) in the presence of a nitrocefin which is the substrate we plan to use in our Biosensor.</p> | ||
<p> First, we wanted to demonstrate that our bacteria carrying the β-lactamase gene were expressing a functional enzyme. (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"> | <p> First, we wanted to demonstrate that our bacteria carrying the β-lactamase gene were expressing a functional enzyme. (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"> | ||
- | <span class="Green"><b> | + | <span class="Green"><b>BBa_K1189007</b></span></a>) was producing functional β-lactamase. In order to do so, we performed an <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/AmpicillinSurvivalAssay1"> |
- | BBa_K1189007 | + | |
- | </b></span> | + | |
- | </a>) was producing functional β-lactamase. In order to do so, we performed an <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/AmpicillinSurvivalAssay1"> | + | |
<span class="Green"><b> | <span class="Green"><b> | ||
Ampicillin Survival Assay 1 | Ampicillin Survival Assay 1 | ||
Line 94: | Line 87: | ||
<img src="https://static.igem.org/mediawiki/2013/thumb/0/03/YYC2013_Blac_Amp_Survival_Assay_with_colonies.jpg/800px-YYC2013_Blac_Amp_Survival_Assay_with_colonies.jpg"> | <img src="https://static.igem.org/mediawiki/2013/thumb/0/03/YYC2013_Blac_Amp_Survival_Assay_with_colonies.jpg/800px-YYC2013_Blac_Amp_Survival_Assay_with_colonies.jpg"> | ||
<figcaption> | <figcaption> | ||
- | <p><b>Figure 6. </b>Absorbance values at 600nm for each tube at four different time points: 0, 30, 60 and 120min. The cultures that expressed β-lactamase (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"> | + | <p><b>Figure 6. </b>Absorbance values at 600nm for each tube at four different time points: 0, 30, 60 and 120min. The cultures that expressed β-lactamase (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"><span class="Green"><b>BBa_K1189007</b></span></a>) showed higher absorbance levels, showing that the cells were able to grow in the presence of ampicillin.</a> |
- | <span class="Green"><b> | + | |
- | BBa_K1189007 | + | |
- | </b></span> | + | |
- | </a>) showed higher absorbance levels, showing that the cells were able to grow in the presence of ampicillin.</a> | + | |
</figcaption> | </figcaption> | ||
- | <p>In addition to that, we have purified our β-lactamase (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"> | + | <p>In addition to that, we have purified our β-lactamase (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"><span class="Green"><b>BBa_K1189007</b></span></a>) and our mobile TALE A linked to β-lactamase construct (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>) (Figure 7) and we have demonstrated that β-lactamase retained its enzymatic activity for both proteins. We repeated a variation of ampicillin survival assay where we pretreated LB containing ampicillin and chloramphenicol with our purified TALE A linked to β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>). We then cultured bacteria in the treated LB that only carry resistance to chloramphenicol. Therefore, the bacteria are only able to survive if the our isolated protein retained its enzymatic abilities. We can show that the bacteria susceptible to ampicillin was able to grow in the presence of our purified construct protein (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>), which means that we are expressing and purifying functional protein which is degrading the ampicillin (Figures 6 and 8). Figure 8 shows the OD at 24 hour time point from culturing where Figure 6 shows OD change over time. Both graphs show an increase in OD for cultures pre-treated with our protein demonstrating our protein is functional.</p> |
- | <span class="Green"><b> | + | |
- | BBa_K1189007 | + | |
- | </b></span> | + | |
- | </a>) and our mobile TALE A linked to β-lactamase construct (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"> | + | |
- | <span class="Green"><b> | + | |
- | BBa_K1189031 | + | |
- | </b></span> | + | |
- | </a >) (Figure 7) and we have demonstrated that β-lactamase retained its enzymatic activity for both proteins. We repeated a variation of ampicillin survival assay where we pretreated LB containing ampicillin and chloramphenicol with our purified TALE A linked to β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"> | + | |
- | <span class="Green"><b> | + | |
- | BBa_K1189031 | + | |
- | </b></span> | + | |
- | </a >). We then cultured bacteria in the treated LB that only carry resistance to chloramphenicol. Therefore, the bacteria are only able to survive if the our isolated protein retained its enzymatic abilities. We can show that the bacteria susceptible to ampicillin was able to grow in the presence of our purified construct protein (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"> | + | |
- | <span class="Green"><b> | + | |
- | BBa_K1189031 | + | |
- | </b></span> | + | |
- | </a >), which means that we are expressing and purifying functional protein which is degrading the ampicillin (Figures 6 and 8). Figure 8 shows the OD at 24 hour time point from culturing where Figure 6 shows OD change over time. Both graphs show an increase in OD for cultures pre-treated with our protein demonstrating our protein is functional.</p> | + | |
<figure> | <figure> | ||
<img src="https://static.igem.org/mediawiki/2013/4/45/YYC2013_TALE_September_22_Blac.jpg"> | <img src="https://static.igem.org/mediawiki/2013/4/45/YYC2013_TALE_September_22_Blac.jpg"> | ||
<figcaption> | <figcaption> | ||
- | <p><b>Figure 7. </b>On the left crude lysate of β-lactamase + His (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"> | + | <p><b>Figure 7. </b>On the left crude lysate of β-lactamase + His (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"><span class="Green"><b>BBa_K1189007<b></span></a>) from different lysis protocols: a <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/GlassBeadsCellLysisProtocolforProteinSamples"> |
- | <span class="Green"><b> | + | |
- | BBa_K1189007 | + | |
- | < | + | |
- | </a>) from different lysis protocols: a <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/GlassBeadsCellLysisProtocolforProteinSamples"> | + | |
<span class="Green"><b> | <span class="Green"><b> | ||
mechanical | mechanical | ||
</b></span> | </b></span> | ||
- | </a> and with <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/OsmoticShock"> | + | </a> and with <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/OsmoticShock"><span class="Green"><b>sucrose</b></span></a>, respectively. On the right, western blot of <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K782004"><span class="Green"><b>TALE A</b></span></a>-linker-β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>) showing that we were able to express and purify our construct. |
- | <span class="Green"><b> | + | |
- | sucrose | + | |
- | </b></span> | + | |
- | </a>, respectively. On the right, western blot of <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K782004"> | + | |
- | <span class="Green"><b> | + | |
- | TALE A | + | |
- | </b></span> | + | |
- | </a>-linker-β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"> | + | |
- | <span class="Green"><b> | + | |
- | BBa_K1189031 | + | |
- | </b></span> | + | |
- | </a>) showing that we were able to express and purify our construct. | + | |
</figcaption> | </figcaption> | ||
<figure> | <figure> | ||
<img src="https://static.igem.org/mediawiki/2013/thumb/3/38/YYC2013_Blac_Amp_Survival_Assay_with_protein_24h.jpg/800px-YYC2013_Blac_Amp_Survival_Assay_with_protein_24h.jpg"> | <img src="https://static.igem.org/mediawiki/2013/thumb/3/38/YYC2013_Blac_Amp_Survival_Assay_with_protein_24h.jpg/800px-YYC2013_Blac_Amp_Survival_Assay_with_protein_24h.jpg"> | ||
<figcaption> | <figcaption> | ||
- | <p><b>Figure 8. </b>Absorbance values at 600nm after 24h. Amounts from 0.1µg to 20µg of TALE A-link-β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"> | + | <p><b>Figure 8. </b>Absorbance values at 600nm after 24h. Amounts from 0.1µg to 20µg of TALE A-link-β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031<b></span></a>) were sufficient to degrade the ampicillin in the media allowing bacteria susceptible to ampicillin to grow.</a> |
- | <span class="Green"><b> | + | |
- | BBa_K1189031 | + | |
- | < | + | |
- | </a >) were sufficient to degrade the ampicillin in the media allowing bacteria susceptible to ampicillin to grow.</a> | + | |
</figcaption> | </figcaption> | ||
<figure> | <figure> |
Revision as of 22:50, 24 October 2013
β-Lactamase
β-Lactamase
What is β-lactamase?
β-lactamase is an enzyme encoded by the ampicillin resistant gene (ampR) frequently present in plasmids for selection. Structurally, β-lactamase is a 29 kDa monomeric enzyme (Figure 1). Its enzymatic activity provides resistance to β-lactam antibiotics such as cephamysin, carbapenems and penicillium through hydrolysis of the β-lactam ring, a structure shared by these antibiotics (Qureshi, 2007).
Many advantages come from working with β-lactamase. It shows high catalytic efficiency and simple kinetics. Also, no orthologs of ampR are known to be encoded by eukaryotic cells and no toxicity was identified making this protein very useful in studies involved eukaryotes (Qureshi, 2007). β-lactamase has been used to track pathogens in infected murine models (Kong et al., 2010). However, in addition to its application in eukaryotic cells, β-lactamase efficiently cleaves a wide variety of substrates but its versatility goes beyond that; ampR preserves its activity even when fused to heterologous protein (Moore et al., 1997). This feature, in particular, makes β-lactamase a potential tool for assembly of synthetic constructs.
How is β-lactamase used as a Reporter?
β-lactamase, in the presence of different substrates, can give various outputs. It can produce a fluorogenic output in the presence of a cephalosporin derivative (CCF2/AM) and enzymatic activity can be detected by a fluorometer (Remy et al., 2007).
Besides fluorescence assays, β-lactamase can also be used to obtain colourimetric outputs by breaking down synthetic compounds such as nitrocefin (Figure 2). The colour change goes from yellow to red (Remy et al., 2007). Colourimetric assays can also be done with benzylpenicillin as the substrate, which, gives a pH output that can be detected with pH indicators to give a colourimetric output (Li et al., 2008).